Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Sanofi plans to reduce its R&D staff of about 10,000 by 466 positions in France and Germany as part of a program to sharpen its research focus. Sanofi’s research priorities will be oncology, immunology, rare diseases, and vaccines. The French drugmaker says it will end new R&D in cardiovascular therapy, continuing only current programs. In diabetes research it will focus on treatments that address the underlying causes of the disease.
This article has been sent to the following recipient: